Drug
BI 764524
BI 764524: highest development phase Phase 2, developed by Boehringer Ingelheim. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| BI 764524 NCT06321302 | Phase 2 | Diabetic Retinopathy |
Latest
No recent events.
Follow BI 764524 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.